Point72 Asset Management »

Lineage Cell Therapeutics In shares owned by Point72 Asset Management

Quarter-by-quarter ownership of Lineage Cell Therapeutics In (LCTX) shares owned by Point72 Asset Management from 13F filings

Historical chart of Point72 Asset Management investment in Lineage Cell Therapeutics In

Tip: Access up to 7 years of quarterly data

All positions including Lineage Cell Therapeutics In held by Point72 Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Lineage Cell Therapeutics In by Point72 Asset Management

Quarter filed Position value Share count Share price at filing
2025-12-31 $266k 159k 1.67
2023-03-31 $21k 14k 1.50

More positions owned by Point72 Asset Management

Spdr S&p 500 Etf Tr Tr Unit Call Option (SPY)
NVIDIA Corporation (NVDA)
Invesco Qqq Tr Unit Ser 1 (QQQ)
Taiwan Semiconductor Mfg Sponsored Ads (TSM)
Amazon (AMZN)
Broadcom (AVGO)
Arista Networks Com Shs (ANET)
Microsoft Corporation (MSFT)
Credo Technology Group Holdi Ordinary Shares (CRDO)
Asml Holding N V N Y Registry Shs (ASML)
Spotify Technology S A SHS (SPOT)
Sea Sponsord Ads (SE)
Biogen Idec (BIIB)
Equinix (EQIX)
Coherent Corp (COHR)

View all positions for Point72 Asset Management

Top funds holding Lineage Cell Therapeutics In

Broadwood Capital
Vanguard Group
Defender Capital
Raffles Associates
Brian McDonald
BlackRock
Millennium Management
Geode Capital Management
Renaissance Technologies
Goldman Sachs Group
Marshall Wace
State Street Corporation
Jane Street
Susquehanna International
Red Crane Wealth Management

View all funds holding Lineage Cell Therapeutics In